These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 18465659)
1. DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders. Elishmereni M; Bachelet I; Levi-Schaffer F Curr Opin Investig Drugs; 2008 May; 9(5):491-6. PubMed ID: 18465659 [TBL] [Abstract][Full Text] [Related]
2. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells. Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979 [TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands. Tahara-Hanaoka S; Miyamoto A; Hara A; Honda S; Shibuya K; Shibuya A Biochem Biophys Res Commun; 2005 Apr; 329(3):996-1000. PubMed ID: 15752754 [TBL] [Abstract][Full Text] [Related]
4. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800 [TBL] [Abstract][Full Text] [Related]
5. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096 [TBL] [Abstract][Full Text] [Related]
6. Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity. Xiong P; Sang HW; Zhu M Immunology; 2015 Nov; 146(3):369-78. PubMed ID: 26235210 [TBL] [Abstract][Full Text] [Related]
8. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. Shibuya A; Lanier LL; Phillips JH J Immunol; 1998 Aug; 161(4):1671-6. PubMed ID: 9712030 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. Liu J; Qian X; Chen Z; Xu X; Gao F; Zhang S; Zhang R; Qi J; Gao GF; Yan J J Immunol; 2012 Jun; 188(11):5511-20. PubMed ID: 22547693 [TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy using NKG2D and DNAM-1 systems. Morisaki T; Onishi H; Katano M Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658 [TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Castriconi R; Dondero A; Corrias MV; Lanino E; Pende D; Moretta L; Bottino C; Moretta A Cancer Res; 2004 Dec; 64(24):9180-4. PubMed ID: 15604290 [TBL] [Abstract][Full Text] [Related]
12. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1. Deuss FA; Watson GM; Goodall KJ; Leece I; Chatterjee S; Fu Z; Thaysen-Andersen M; Andrews DM; Rossjohn J; Berry R J Biol Chem; 2019 Aug; 294(33):12534-12546. PubMed ID: 31253644 [TBL] [Abstract][Full Text] [Related]
13. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses. Shibuya A; Shibuya K Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361 [TBL] [Abstract][Full Text] [Related]
14. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766 [TBL] [Abstract][Full Text] [Related]
15. Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226). Shirakawa J; Shibuya K; Shibuya A Int Immunol; 2005 Mar; 17(3):217-23. PubMed ID: 15684041 [TBL] [Abstract][Full Text] [Related]
16. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862 [TBL] [Abstract][Full Text] [Related]
17. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980 [TBL] [Abstract][Full Text] [Related]
18. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389 [TBL] [Abstract][Full Text] [Related]
19. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. de Andrade LF; Smyth MJ; Martinet L Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663 [TBL] [Abstract][Full Text] [Related]
20. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. Stein N; Tsukerman P; Mandelboim O Hum Antibodies; 2017; 25(3-4):111-119. PubMed ID: 28035916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]